Valence8 US’s Ultragenyx Pharmaceutical RARE Stock Holding History

Valence8 US’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,241	Closed	-$236K	–	51
2024 Q3	$236K	Buy	+4,241	New	+$216K	0.1%	41

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Valence8 US's RARE Position: Q4 2024 in Review

Valence8 US sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 4,241 shares — an estimated $236K sold.

Valence8 US first reported a position in RARE in Q3 2024 and held it in 1 quarter. The position peaked at $236K in Q3 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

Valence8 US reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 4,241 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $236K.
Valence8 US first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 1 quarter.
Valence8 US's Ultragenyx Pharmaceutical position peaked at $236K in Q3 2024.
312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.